RecruitingNot ApplicableNCT05705804

Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial


Sponsor

Yonsei University

Enrollment

250 participants

Start Date

Jun 13, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study was to investigate the effect of pitavastatin or pitavastatin and ezetimibe combination therapy on glucose metabolism compared to atorvastatin in patients with atherosclerotic cardiovascular disease with metabolic syndrome.


Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Atorvastatin, a drug called Pitavastatin, and others for people with atherosclerotic cardiovascular disease and dyslipidemias. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPitavastatin

Pitavastatin 4 mg will be given.

DRUGPitavastatin plus Ezetemibe

Pitvastatin 4 mg plus ezetemibe 10 mg will be given.

DRUGAtorvastatin

Atorvastatin 40 mg will be given.


Locations(1)

Yonsei University Health System, Severance Hospital

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05705804


Related Trials